Citius Pharmaceuticals, INC. (CTXR) — 10-Q Filings

10-Q Filings (6)

• Citius Pharma's Q2 Loss Widens Amid R&D Spend — Aug 12, 2025 Risk: high
  Citius Pharmaceuticals, Inc. (CTXR) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-commercial stage as a pharmaceutical compan
• Citius Pharmaceuticals Files Q1 2025 10-Q — May 14, 2025 Risk: medium
  Citius Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended March 31, 2025. The company, incorporated in Nevada, is focused on pha
• Citius Pharmaceuticals Files 10-Q for Q4 2024 — Feb 14, 2025 Risk: low
  Citius Pharmaceuticals, Inc. filed its 10-Q for the quarterly period ended December 31, 2024. The company, incorporated in Nevada, is involved in the pharmaceut
• Citius Pharmaceuticals Files Q2 2024 10-Q Report — Aug 12, 2024 Risk: low
  Citius Pharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2024. The company, incorporated in Nevada, is involved in the
• Citius Pharmaceuticals, Inc. Files Quarterly Report (10-Q) for Period Ended March 31, 2024 — May 14, 2024 Risk: low
  Citius Pharmaceuticals, Inc. (CTXR) filed a Quarterly Report (10-Q) with the SEC on May 14, 2024. Citius Pharmaceuticals, Inc. filed a 10-Q report for the quart
• Citius Pharmaceuticals, Inc. Files 10-Q for Period Ended December 31, 2023 — Feb 14, 2024 Risk: low
  Citius Pharmaceuticals, Inc. (CTXR) filed a Quarterly Report (10-Q) with the SEC on February 14, 2024. Citius Pharmaceuticals, Inc. filed a 10-Q report for the

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX